Department of Receptor Biology and Tumor Metastasis, Chittaranjan National Cancer Institute, Kolkata, India.
Department of Gynaecological Oncology, Chittaranjan Cancer Hospital, Kolkata, India.
Biomed Res Int. 2022 Apr 20;2022:5346091. doi: 10.1155/2022/5346091. eCollection 2022.
Ovarian cancer (OvCa), the deadliest gynaecological malignancy, is associated with poor prognosis and high mortality rate. Ovarian cancer has been related with CA-125 and metabolic reprogramming by SIRT1 leading to metastasis with the involvement of exosomes.
Clinicopathological data of OvCa patients were collected to perform the analysis. Patients' samples were collected during surgery for immunohistochemistry and flow cytometric analysis of SIRT1, HIF-1, exosomal markers (CD81 and CD63), ki-67, and PAS staining for glycogen deposition. Adjacent normal and tumor tissues were collected as per the CA-125 levels.
CA-125, a vital diagnostic marker, has shown significant correlation with body mass index (BMI) ( = 0.0153), tumor type ( = 0.0029), ascites level, ascites malignancy, degree of dissemination, tumor differentiation, FIGO stage, TNM stage, laterality, and tumor size at < 0.0001. Since significant correlation was associated with BMI and degree of dissemination, as disclosed by IHC analysis, metabolic marker SIRT1 ( = 0.0003), HIF-1 ( < 0.0001), exosomal marker CD81 ( < 0.0001), ki-67 status ( = 0.0034), and glycogen deposition ( <0.0001) were expressed more in tumor tissues as compared to the normal ones. ROC analysis of CA-125 had shown 327.7 U/ml has the best cutoff point with 82.4% sensitivity and specificity of 52.3%. In addition, Kaplan-Meier plots of CA-125 ( < 0.0001), BMI ( = 0.001), degree of dissemination ( < 0.0001), and ascites level ( <0.0001) reflected significant correlation with overall survival (OS). Upon multivariate Cox-regression analysis for overall survival (OS), BMI ( = 0.008, HR 1.759, 95% CI 1.156-2.677), ascites malignancy ( = 0.032, HR 0.336, 95% CI 0.124-0.911), and degree of dissemination ( = 0.004, HR 1.994, 95% CI 1.251-3.178) were significant proving to be independent indicators of the disease.
Clinicopathological parameters like BMI, degree of dissemination, and ascites level along with CA-125 can be prognostic factors for the disease. Levels of CA-125 can depict the metabolic and metastatic factors. Thus, by targeting SIRT1 and assessing exosomal concentrations to overcome metastasis and glycogen deposition, individualized treatment strategy could be designed. In-depth studies are still required.
卵巢癌(OvCa)是致命的妇科恶性肿瘤,预后不良,死亡率高。卵巢癌与 CA-125 有关,与 SIRT1 引起的代谢重编程有关,导致转移,涉及外泌体。
收集卵巢癌患者的临床病理数据进行分析。在手术过程中收集患者样本,进行 SIRT1、HIF-1、外泌体标志物(CD81 和 CD63)、ki-67 和 PAS 染色以检测糖原沉积的免疫组织化学和流式细胞术分析。根据 CA-125 水平收集相邻的正常和肿瘤组织。
CA-125 是一种重要的诊断标志物,与体重指数(BMI)(= 0.0153)、肿瘤类型(= 0.0029)、腹水水平、腹水恶性程度、播散程度、肿瘤分化、FIGO 分期、TNM 分期、侧别和肿瘤大小显著相关(<0.0001)。由于 IHC 分析显示与 BMI 和播散程度相关,代谢标志物 SIRT1(= 0.0003)、HIF-1(<0.0001)、外泌体标志物 CD81(<0.0001)、ki-67 状态(= 0.0034)和糖原沉积(<0.0001)在肿瘤组织中的表达高于正常组织。CA-125 的 ROC 分析显示 327.7 U/ml 具有最佳截断点,灵敏度为 82.4%,特异性为 52.3%。此外,CA-125(<0.0001)、BMI(= 0.001)、播散程度(<0.0001)和腹水水平(<0.0001)的 Kaplan-Meier 图反映了与总生存(OS)的显著相关性。多变量 Cox 回归分析总生存(OS),BMI(= 0.008,HR 1.759,95%CI 1.156-2.677)、腹水恶性程度(= 0.032,HR 0.336,95%CI 0.124-0.911)和播散程度(= 0.004,HR 1.994,95%CI 1.251-3.178)是独立的疾病预后指标。
BMI、播散程度和腹水水平等临床病理参数以及 CA-125 可作为疾病的预后因素。CA-125 水平可以描绘代谢和转移因素。因此,通过靶向 SIRT1 并评估外泌体浓度以克服转移和糖原沉积,可以设计个体化治疗策略。仍需要进一步的研究。